Clinical Trial Update: Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating PDE5 inhibitors in single-ventricle patients with pulmonary hypertension was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Single-ventricle Physiology
• Univentricular Heart

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Single-ventricle, Pulmonary Hypertension | Phase 3 | Status: WITHDRAWN